Deferiprone Patent Expiration
Deferiprone is Used for managing transfusional iron overload. It was first introduced by Chiesi Usa Inc
Deferiprone Patents
Given below is the list of patents protecting Deferiprone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ferriprox | US10780055 | Delayed release deferiprone tablets and methods of using the same | Oct 25, 2038 | Chiesi |
| Ferriprox | US10940115 | Delayed release deferiprone tablets and methods of using the same | Oct 25, 2038 | Chiesi |
| Ferriprox | US10940116 | Delayed release deferiprone tablets and methods of using the same | Oct 25, 2038 | Chiesi |
| Ferriprox | US11357731 | Delayed release deferiprone tablets and methods of using the same | Oct 25, 2038 | Chiesi |
| Ferriprox | US11458103 | Delayed release deferiprone tablets and methods of using the same | Oct 25, 2038 | Chiesi |
| Ferriprox | US11723874 | Delayed release deferiprone tablets and methods of using the same | Oct 25, 2038 | Chiesi |
| Ferriprox | US8703156 | Liquid formulation for deferiprone with palatable taste | Oct 26, 2029 | Chiesi |
| Ferriprox | US7049328 | Use for deferiprone |
Jun 28, 2021
(Expired) | Chiesi |
Deferiprone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Deferiprone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Ferritin and Iron Burden in SAH sIRB | Duke University | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients | Rohan Dharmakumar | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |